Developer docs
API playgroundTry for free, no card

Search company profiles

BIND Therapeutics

Full company profile

uuid00373fv

Namestring
BIND Therapeutics
Company typeenum
Private
Founded yearint
2006
Descriptiontext

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics intended to concentrate drug activity at disease sites while limiting exposure to healthy tissue. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company built its operating model around proprietary nanoparticle engineering — encapsulating therapeutic payloads within targeted nanoparticles designed to bind to specific cells or tissues. The platform positioned BIND as a programmable delivery system applicable across multiple therapeutic payloads and disease areas.\n\nThe company served the pharmaceutical R&D market rather than end patients directly. As a clinical-stage entity, BIND generated no commercial product revenue. Its go-to-market and revenue mechanics depended on advancing Accurins candidates through preclinical and clinical development, then either licensing or co-developing with larger pharmaceutical partners for milestone and royalty payments, or being acquired outright. Capitalization has been driven by venture financing — approximately $91.85 million disclosed across seven rounds from 2007 through 2015 — led by syndicates including ARCH Venture Partners, Flagship Pioneering, Polaris Partners, ND Capital, Endeavour Vision, and RUSNANO. The company also accessed public markets via a NASDAQ listing under ticker BIND, which is now delisted; the input does not specify the listing or delisting dates.\n\nConfirmed leadership on the public record is limited to Daniel Lynch as Chairman of the Board and Jim Wright as Chief Scientific Officer. Broader operating team composition, pipeline progression, and post-2015 operating activity are not disclosed in the available input, indicating either limited post-delisting public footprint or material data gaps.

Short descriptiontext

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted nanoparticle therapeutics, headquartered in Cambridge, Massachusetts.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
targeted nanomedicine therapeutics, polymeric nanoparticle platform, clinical-stage drug delivery, precision oncology drugs, nanoparticle drug delivery
Industry2 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Research and Development in Nanotechnology541713
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Nanomedicine Therapeutics
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a proprietary class of highly selective, targeted polymeric nanoparticle therapeutics. These therapeutics are engineered to deliver drug payloads preferentially to diseased cells while minimizing exposure to healthy tissue, addressing limitations of conventional drug delivery in oncology and other disease areas.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Accurins Platform
CategoryTargeted Nanomedicine Therapeutics
Description

A proprietary class of highly selective, targeted polymeric nanoparticle therapeutics engineered to deliver drug payloads directly to diseased cells while sparing healthy tissue. Designed for pharmaceutical partners developing treatments in oncology and other disease areas.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Commercial-stage Swedish company commercializing nanoscale drug delivery using its proprietary FluidCrystal® technology. Directly comparable in developing engineered nanoscale delivery solutions for poorly soluble and targeted therapeutics.

TypeDirect peer
Description

Clinical-stage company developing targeted RNAi therapeutics via its TRIM™ and other proprietary delivery platforms. Closely comparable in applying targeted nanoparticle delivery across multiple therapeutic programs.

3Selecta Biosciences
TypeDirect peer
Description

Clinical-stage company developing synthetic nanoparticle therapeutics for immunomodulation and targeted delivery. Directly comparable to BIND as a nanoparticle-platform biotech with similar payload-flexibility strategy.

TypeBroad incumbent
Description

Commercial-stage leader in RNAi therapeutics using lipid nanoparticle and GalNAc conjugate delivery systems. A broader-incumbent comparable: a targeted-therapeutics platform company with validated clinical and commercial nanoparticle delivery at much larger scale.

5NanoCarrier
TypeDirect peer
Description

Japanese clinical-stage biotech developing polymeric micelle nanoparticle therapeutics (e.g., NC-6004, NC-6300). Closely comparable to BIND's Accurin approach of encapsulating payloads in polymeric nanoparticles for targeted delivery.

TypeBroad incumbent
Description

Commercial-stage mRNA therapeutics company with industry-leading lipid nanoparticle delivery platform. Comparable as a nanoparticle-based therapeutics platform company, though far larger in scale and capital.

TypeDirect peer
Description

Develops lipid nanoparticle-enabled RNA therapeutics. Comparable to BIND as a clinical-stage platform company whose core value rests on engineered nanoparticle delivery technology applied to multiple payload classes.

TypeEmerging player
Description

Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics and has major partnerships with large pharma. Comparable as a technology-provider-model nanoparticle delivery company, though more focused on nucleic acid payloads.

TypeEmerging player
Description

European clinical-stage biotech developing polymeric nanoparticle therapeutics (CriPec® platform). Highly comparable to BIND's polymeric nanoparticle delivery technology and clinical-stage positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIND Therapeutics

Targeted Nanomedicine Therapeuticsbindtherapeutics.com

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted nanoparticle therapeutics, headquartered in Cambridge, Massachusetts.

What BIND Therapeutics does

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics intended to concentrate drug activity at disease sites while limiting exposure to healthy tissue. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company built its operating model around proprietary nanoparticle engineering — encapsulating therapeutic payloads within targeted nanoparticles designed to bind to specific cells or tissues. The platform positioned BIND as a programmable delivery system applicable across multiple therapeutic payloads and disease areas.\n\nThe company served the pharmaceutical R&D market rather than end patients directly. As a clinical-stage entity, BIND generated no commercial product revenue. Its go-to-market and revenue mechanics depended on advancing Accurins candidates through preclinical and clinical development, then either licensing or co-developing with larger pharmaceutical partners for milestone and royalty payments, or being acquired outright. Capitalization has been driven by venture financing — approximately $91.85 million disclosed across seven rounds from 2007 through 2015 — led by syndicates including ARCH Venture Partners, Flagship Pioneering, Polaris Partners, ND Capital, Endeavour Vision, and RUSNANO. The company also accessed public markets via a NASDAQ listing under ticker BIND, which is now delisted; the input does not specify the listing or delisting dates.\n\nConfirmed leadership on the public record is limited to Daniel Lynch as Chairman of the Board and Jim Wright as Chief Scientific Officer. Broader operating team composition, pipeline progression, and post-2015 operating activity are not disclosed in the available input, indicating either limited post-delisting public footprint or material data gaps.

BIND Therapeutics firmographics

Firmographics
Name
BIND Therapeutics
Website
https://bindtherapeutics.com
Company type
Private
Founded year
2006
Headcount range
1–10 employees
Short description
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted nanoparticle therapeutics, headquartered in Cambridge, Massachusetts.
Ownership category
akta.pro rank

BIND Therapeutics industry classification

Industry
Product category
Targeted Nanomedicine Therapeutics
NAICS
Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Targeted nanomedicine therapeutics
  • Polymeric nanoparticle platform
  • Clinical-stage drug delivery
  • Precision oncology drugs
  • Nanoparticle drug delivery

Where BIND Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

BIND Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

BIND Therapeutics product offering

Product offering

Core offering

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a proprietary class of highly selective, targeted polymeric nanoparticle therapeutics. These therapeutics are engineered to deliver drug payloads preferentially to diseased cells while minimizing exposure to healthy tissue, addressing limitations of conventional drug delivery in oncology and other disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Accurins Platform A proprietary class of highly selective, targeted polymeric nanoparticle therapeutics engineered to deliver drug payloads directly to diseased cells while sparing healthy tissue. Designed for pharmaceutical partners developing treatments in oncology and other disease areas.

Companies that use BIND Therapeutics

Customer profile

Ideal customer profiles1 record

BIND Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BIND Therapeutics partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

BIND Therapeutics competitors and assessment

Company assessment

Direct peers

  • Camurus: Commercial-stage Swedish company commercializing nanoscale drug delivery using its proprietary FluidCrystal® technology. Directly comparable in developing engineered nanoscale delivery solutions for poorly soluble and targeted therapeutics.
  • Arrowhead Pharmaceuticals: Clinical-stage company developing targeted RNAi therapeutics via its TRIM™ and other proprietary delivery platforms. Closely comparable in applying targeted nanoparticle delivery across multiple therapeutic programs.
  • Selecta Biosciences: Clinical-stage company developing synthetic nanoparticle therapeutics for immunomodulation and targeted delivery. Directly comparable to BIND as a nanoparticle-platform biotech with similar payload-flexibility strategy.
  • NanoCarrier: Japanese clinical-stage biotech developing polymeric micelle nanoparticle therapeutics (e.g., NC-6004, NC-6300). Closely comparable to BIND's Accurin approach of encapsulating payloads in polymeric nanoparticles for targeted delivery.
  • Arcturus Therapeutics: Develops lipid nanoparticle-enabled RNA therapeutics. Comparable to BIND as a clinical-stage platform company whose core value rests on engineered nanoparticle delivery technology applied to multiple payload classes.

Broad incumbents

  • Alnylam Pharmaceuticals: Commercial-stage leader in RNAi therapeutics using lipid nanoparticle and GalNAc conjugate delivery systems. A broader-incumbent comparable: a targeted-therapeutics platform company with validated clinical and commercial nanoparticle delivery at much larger scale.
  • Moderna: Commercial-stage mRNA therapeutics company with industry-leading lipid nanoparticle delivery platform. Comparable as a nanoparticle-based therapeutics platform company, though far larger in scale and capital.

Emerging players

  • Acuitas Therapeutics: Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics and has major partnerships with large pharma. Comparable as a technology-provider-model nanoparticle delivery company, though more focused on nucleic acid payloads.
  • Cristal Therapeutics: European clinical-stage biotech developing polymeric nanoparticle therapeutics (CriPec® platform). Highly comparable to BIND's polymeric nanoparticle delivery technology and clinical-stage positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

BIND Therapeutics social profiles

Digital presence

BIND Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIND Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

BIND Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIND Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIND Therapeutics

What does BIND Therapeutics do?

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a proprietary class of highly selective, targeted polymeric nanoparticle therapeutics. These therapeutics are engineered to deliver drug payloads preferentially to diseased cells while minimizing exposure to healthy tissue, addressing limitations of conventional drug delivery in oncology and other disease areas.

When was BIND Therapeutics founded?

BIND Therapeutics was founded in 2006. It employs 1 to 10 people.

Where is BIND Therapeutics based?

BIND Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are BIND Therapeutics's main competitors?

Direct peers on record are Camurus, Arrowhead Pharmaceuticals, Selecta Biosciences, NanoCarrier and Arcturus Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Moderna. Emerging players are Acuitas Therapeutics and Cristal Therapeutics.

Does BIND Therapeutics have an API?

No public API is recorded for BIND Therapeutics.

What industry is BIND Therapeutics in?

BIND Therapeutics's product category is Targeted Nanomedicine Therapeutics. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 541713 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogThe Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value DestructionThe Radoff-JEC Group, owning about 7.7% of Seer, Inc., issued a proxy statement urging stockholders to vote for three new independent directors. The group cites a 97% share price decline since Seer's 2020 IPO and past failures by CEO Omid Farokhzad. They seek support at the July 28, 2026 annual meeting.EIN PresswireNanomedicine Market Advances Rapidly with Expanding Size, Share, Innovation-Driven Trends and a Strong Forecast to 2032Maximize Market Research published a market report estimating the global Nanomedicine Market at USD 207.91 billion in 2025, projecting growth to USD 462.50 billion by 2032 at a CAGR of 12.1%, driven by advances in precision nanoparticle drug delivery, nano-enabled diagnostics, and regenerative medical devices. Specific corporate developments cited include Elan Corporation advancing a flexible nano-drug delivery patch via joint venture (May 14, 2025), Ablynx securing a €2.1 million grant for eye disease Nanobodies (December 3, 2025), and BIND Therapeutics progressing its Medicinal Nanoengineering platform through Accurin collaborations (March 18, 2025). North America leads the market with a 43.78% share, while Asia Pacific, led by China and Japan, is emerging as a growth hub supported by government nanotechnology initiatives.EIN PresswireNanomedicine Market Advances Rapidly with Expanding Size, Share, Innovation-Driven Trends and a Strong Forecast to 2032The global nanomedicine market is valued at USD 207.91 billion in 2025 and projected to reach USD 462.50 billion by 2032, growing at a CAGR of 12.1%, driven by advances in precision nanoparticle drug delivery, nano-enabled diagnostics, and regenerative medical devices. Three companies made specific reported developments: Elan Corporation advanced flexible nano-drug delivery patch technology via a joint venture, Ablynx secured a €2.1M grant for eye disease Nanobodies, and BIND Therapeutics progressed its Medicinal Nanoengineering platform through Accurin collaborations. Growth is constrained by high manufacturing costs, complex regulatory processes, and talent shortages, while North America dominates the market with a 43.78% share and Asia Pacific emerges as a key innovation hub.News-MedicalMeasuring Nanoparticles for Drug Delivery ApplicationsEntegris installed an at-line dynamic light scattering system in BIND Therapeutics' Accurins production to monitor particle size. The system showed a size-pressure correlation of 9 nm per 1,000 psig and kept all eight clinical-scale measurements within the 100 nm target range. The at-line monitoring reduced lag time and enabled real-time process adjustments.GlobeNewswireDelisting of Securities of BIND Therapeutics, Inc.,Nasdaq announced delisting of BIND Therapeutics' common stock, along with InterCloud Systems, Echo Therapeutics, 1347 Capital Corp, and EPIRUS Biopharmaceuticals. Each stock was suspended and had not traded since, and delistings become effective ten days after Nasdaq files Form 25 with the SEC.PR NewswireBiotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron PharmaThis August 3, 2016 technical report covers stock performance and recent developments for four biotech companies: Arena Pharmaceuticals, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharmaceuticals. Key events include Pfizer acquiring substantially all of BIND Therapeutics' assets for $40 million through a Section 363 bankruptcy auction, Arena Pharma receiving FDA approval for BELVIQ XR with a $10 million milestone payment, and Regeneron and Sanofi gaining EMA acceptance for their sarilumab marketing application for rheumatoid arthritis treatment. The broader biotech sector drove the NYSE Arca Biotechnology Index up 2.4% on August 1, 2016.AstrazenecaAstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicineAstraZeneca and BIND Therapeutics announced a strategic collaboration on April 22, 2013, to develop and commercialize Accurin, a targeted cancer nanomedicine derived from BIND's Medicinal Nanoengineering platform using a kinase inhibitor from AstraZeneca. Under the agreement, AstraZeneca receives exclusive worldwide development and commercialization rights while BIND leads manufacturing and could receive upfront and pre-approval milestone payments totaling $69 million, plus over $130 million in regulatory and sales milestones along with tiered royalties on future sales. The deal followed successful results from a feasibility program and represents a significant partnership in the emerging field of nanoparticle-based cancer therapeutics.